Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Appointed CFO
Quarterly results
Auditor change
|
|
Eledon Pharmaceuticals, Inc. (NVUS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 06/08/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/18/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Departure of Directors or Certain Office...|
Docs:
|
"PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK ELEDON PHARMACEUTICALS, INC. Warrant Shares: _______ Issue Date:______, 20__ Initial Exercise Date: _______, 20__ THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Eledon Pharmaceuticals, Inc., a Delaware corporation , up to ______ shares of the Company’s common stock, par value $0.001 per share . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Se...",
"TRANCHE A WARRANT TO PURCHASE COMMON STOCK",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of April 28, 2023, between Eledon Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements contained in Section 4 of the Securities Act of 1933, as amended , and/or Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consid...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of April 28, 2023, by and between Eledon Pharmaceuticals, Inc., a Delaware corporation , and each of the several purchasers signatory hereto . This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser . The Company and each Purchaser hereby agrees as follows: 1. Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “Advice” shall have the meaning set forth in Section 6. “Effectiveness Dateȁ...",
"Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials $35 million in upfront financing with the potential to receive additional aggregate financing up to $105 million, subject to achieving clinical development milestones, plus up to $45 million upon exercise of warrants Led by BVF Partners LP and Armistice Capital, with participation from new investor Sanofi Aggregate financing expected to be sufficient to fund Company through the completion of the Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in patients receiving a kidney transplant" |
|
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Eledon Pharmaceuticals, Inc. |
| 01/09/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 06/22/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/24/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/24/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.9% stake in Eledon Pharmaceuticals, Inc. |
| 02/11/2022 |
SC 13G/A
| Woodline Partners LP reports a 4.8% stake in Eledon Pharmaceuticals, Inc. |
| 02/10/2022 |
SC 13G/A
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 0% stake in Eledon Pharmaceuticals, Inc. |
| 02/09/2022 |
SC 13G/A
| FMR LLC reports a 3.5% stake in ELEDON PHARMACEUTICALS INC |
| 01/28/2022 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 16.9% stake in Eledon Pharmaceuticals, Inc. |
| 01/26/2022 |
SC 13G/A
| Logos Global Management LP reports a 0% stake in Eledon Pharmaceuticals, Inc. |
| 01/13/2022 |
8-K
| Unregistered Sales of Equity Securities, Financial Statements and Exhibits Interactive Data |
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/12/2021 |
8-K
| Quarterly results |
|
|
|